摘要
目的探讨和分析益生菌预防早产儿坏死性小肠结肠炎(NEC)的临床疗效。方法此次研究选择该院在2014年12月—2016年12月期间收治的114例早产儿作为研究主体,按照早产儿入院顺序分为甲组和乙组,每组各57例早产儿,甲乙两组患儿均进行原发病治疗,甲组早产儿加用双岐杆菌四联活菌片,对比甲乙两组早产儿NEC的发生情况、Bell分期情况以及死亡情况。结果甲组早产儿NEC的发生率(3.51%)少于乙组早产儿(15.79%),差异有统计学意义(χ~2=4.930,P=0.026)。甲组早产儿NEC的发展成Bell分期≥2的概率(1.75%)少于乙组(12.28%),差异有统计学意义(χ~2=4.840,P=0.028)。甲组早产儿的死亡率(0.00%)少于乙组早产儿(7.02%),差异有统计学意义(χ~2=4.146,P=0.042)。结论双岐杆菌四联活菌片在早产儿中的应用效果良好,有效降低了早产儿坏死性小肠结肠炎发生的风险,值得推广。
Objective To study and analyze the clinical curative effect of Probiotics in preventing the Necrotizing enterocolitis in premature infants. Methods 114 cases of premature infants admitted and treated in our hospital from December 2014 to December 2016 were selected and divided into two groups with 57 cases in each, both groups adopted the primary disease treatment, and the group A added the bifidobacterium tetravaccine tablets, and the occurrence of NEX, Bell staging situation and death situation were compared between the two groups. Results The incidence rate of NEC in the group A was fewer than that in the group B,（3.51% vs 15.79%）,and the difference was obvious with statistical significant（χ^2=4.930,P=0.026）, and the development probability into Bell stage ≥2 in the group A was fewer than that in the group B（1.75% vs 12.28%）, and the difference was statistically significant,（χ^2=4.840,P =0.028）, and the death rate in the group A was fewer than that in the group B（0.00% vs 7.02%）, and the difference was statistically significant（χ^2=4.146,P=0.042）. Conclusion The application effect of bifidobacterium tetravaccine tablets in the premature infants is good, which can effectively reduce the occurrence risk of necrotizing enterocolitis in premature infants, which is worth promotion.
出处
《世界复合医学》
2017年第3期67-69,共3页
World Journal of Complex Medicine
关键词
双歧杆菌四联活菌
早产儿坏死性小肠结肠炎
临床效果
Bifidobacterium tetravaccine tablets
Necrotizing enterocolitis in premature infants
Clinical effect
